ANTXR1 Gene Hemangioma Capillary Infantile NGS Genetic DNA Test
Comprehensive Genetic Testing for Infantile Capillary Hemangioma
The ANTXR1 Gene Hemangioma Capillary Infantile NGS Genetic DNA Test represents a cutting-edge diagnostic approach for identifying genetic mutations associated with infantile capillary hemangioma. This specialized test utilizes next-generation sequencing (NGS) technology to provide comprehensive analysis of the ANTXR1 gene, which plays a crucial role in vascular development and tumor formation in infants.
What This Test Measures and Detects
This advanced genetic test specifically targets mutations in the ANTXR1 (Anthrax Toxin Receptor 1) gene, which has been identified as a key genetic factor in the development of infantile capillary hemangiomas. The test examines:
- Point mutations and single nucleotide variations in the ANTXR1 gene
- Insertions and deletions affecting gene function
- Copy number variations and structural alterations
- Regulatory region mutations impacting gene expression
Who Should Consider This Test
This genetic test is particularly recommended for:
- Infants presenting with characteristic red birthmarks or vascular lesions
- Children with rapidly growing hemangiomas requiring medical intervention
- Families with a history of infantile hemangioma in multiple generations
- Cases where conventional diagnosis remains uncertain
- Patients requiring genetic confirmation for treatment planning
Clinical Symptoms and Indications
Infants who may benefit from this testing typically present with:
- Bright red, raised vascular birthmarks appearing in early infancy
- Rapidly proliferating vascular lesions during the first year of life
- Hemangiomas affecting critical areas such as the face, eyes, or airways
- Multiple hemangiomas occurring simultaneously
- Complications including ulceration, bleeding, or functional impairment
Benefits of Genetic Testing for Infantile Hemangioma
Early Intervention and Treatment Planning
Genetic confirmation through the ANTXR1 test enables healthcare providers to implement targeted treatment strategies earlier in the disease course. This can significantly improve outcomes and reduce complications associated with progressive hemangioma growth.
Family Genetic Counseling
Understanding the genetic basis of infantile hemangioma provides families with valuable information about recurrence risks in future pregnancies. This knowledge supports informed family planning decisions and prepares parents for potential medical needs.
Personalized Medical Management
Genetic test results help oncologists and pediatric specialists develop individualized treatment protocols based on the specific mutation identified, potentially improving therapeutic efficacy and reducing unnecessary interventions.
Understanding Your Test Results
Positive Result Interpretation
A positive result indicates the presence of a pathogenic mutation in the ANTXR1 gene associated with infantile capillary hemangioma. This confirmation enables:
- Implementation of appropriate monitoring protocols
- Early intervention with targeted therapies
- Comprehensive family genetic counseling
- Long-term follow-up planning
Negative Result Interpretation
A negative result suggests that no pathogenic mutations were detected in the ANTXR1 gene. However, this does not completely rule out the possibility of hemangioma development through other genetic or environmental factors. Further evaluation may be recommended based on clinical presentation.
Variant of Uncertain Significance
In some cases, the test may identify genetic variations whose clinical significance is not yet fully understood. These results require careful interpretation by genetic specialists and may warrant additional family studies or periodic re-evaluation as scientific knowledge advances.
Test Information and Pricing
| Test Component | Details |
|---|---|
| Test Name | ANTXR1 Gene Hemangioma Capillary Infantile NGS Genetic DNA Test |
| Discount Price | $500 USD |
| Regular Price | $700 USD |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type | Blood, Extracted DNA, or One Drop Blood on FTA Card |
| Testing Method | Next-Generation Sequencing (NGS) Technology |
| Specialty | Oncologist |
| Department | Genetics |
Pre-Test Requirements
Before undergoing the ANTXR1 Gene Hemangioma Capillary Infantile NGS Genetic DNA Test, patients should provide:
- Complete clinical history of the patient
- Genetic counseling session to create a detailed family pedigree chart
- Documentation of affected family members with similar conditions
- Current medical records and diagnostic imaging if available
Nationwide Accessibility
GGC DNA maintains comprehensive testing facilities across the United States, with branches conveniently located in all major metropolitan areas including:
- New York City and surrounding regions
- Los Angeles and Southern California
- Chicago and the Midwest
- Houston and Texas medical centers
- Miami and Florida healthcare networks
- Seattle and Pacific Northwest facilities
Take Action Today
Don’t wait to get the critical genetic information you need for your infant’s health. Early detection of ANTXR1 gene mutations can significantly impact treatment outcomes and provide peace of mind for your family.
Call or WhatsApp us today at +1(267) 388-9828 to schedule your genetic counseling session and book the ANTXR1 Gene Hemangioma Capillary Infantile NGS Genetic DNA Test.
Our dedicated genetic specialists are available to answer your questions, explain the testing process, and help you understand how this advanced genetic analysis can benefit your child’s healthcare journey.
